Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01024244 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2599506 in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT01024244 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 78 participants.
The verdict
NCT01024244, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
The purpose of this study is to help answer the following questions: * To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks. * To evaluate the safety of LY2599506 in participants with diabetes. * To determine if LY2599506 has the ability to control blood sugar in participants with diabetes. * To determine how much LY2599506 should be given to participants. * To determine if LY2599506 has an effect on a participant's weight. The study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8-week treatment period, and a 4-week follow-up period.
Interventions
- DRUG Placebo
- DRUG LY2599506
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01024244
The ClinicalTrials.gov registry entry for NCT01024244 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01024244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01024244 about?
NCT01024244 is a clinical study titled "A Study of LY2599506 in Patients With Type 2 Diabetes". The purpose of this study is to help answer the following questions: * To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks. * To evaluate the safety of LY2599506 in participants with diabetes. * To determine if LY2599506 has the ability to control b...
What is the current status of trial NCT01024244?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2009-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01024244?
The interventions under investigation include: Placebo (DRUG), LY2599506 (DRUG).
Who is sponsoring clinical trial NCT01024244?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.